Giordano Michael F 4

What Happened

• Michael F. Giordano, a non-employee director of RAPT Therapeutics (RAPT), was granted 4,956 restricted stock units (RSUs) on January 30, 2026. The grant was recorded at $0.00 per RSU (total reported value $0) because RSUs represent contingent rights to shares rather than an immediate cash purchase.

Key Details

• Transaction date: 2026-01-30; grant type: Award/Grant (code A); price per share: $0.00; units: 4,956 RSUs.
• Vesting: Per footnote F1, these RSUs fully vest on the first anniversary of the grant date (each RSU converts to one share upon vesting).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing: Form 4 filed 2026-02-02 — within the SEC’s two-business-day reporting window (timely).

Context

• This is a routine annual equity grant under RAPT’s Amended & Restated Non-Employee Director Compensation Policy for directors, not an open-market purchase or sale. RSU awards are common director compensation and do not represent immediate share purchases; they only become owned shares if and when they vest (and may be subject to tax withholding at vesting).